Overview
atai Life Sciences is a publicly listed biotech platform company building a portfolio of clinical-stage mental health companies developing psychedelic and non-psychedelic treatments for depression, PTSD, anxiety, and addiction. Their subsidiaries include programs using psilocybin, DMT, MDMA, and novel compounds.
More in Psychedelics
Latest industry news
FDA Grants De Novo Approval to Modius Spero, Clearing First Neuromodulation Device for PTSD
2026-09-03 · Policy
Butterfly Network's BCI Chip Licensing Deal Rattles Investors as Shares Drop Nearly 10%
2026-09-02 · Industry
Merge Labs and Butterfly Network Unite to Push Ultrasound-Based BCIs Into the Mainstream
2026-09-01 · Industry
FDA Grants CorTec Second Breakthrough Device Designation for Its Brain-Computer Interface
2026-08-31 · Policy
Company details
Category
🍄 Psychedelics
Location
Berlin, Germany
Funding
Public · NASDAQ: ATAI
Website
www.atai.lifeListed
2026-06-15
Is this your company?
Claim this listing to add your logo, full description, team, and products. Premium listings get featured placement.
Claim & upgrade listingAdvertise
Reach neurotech professionals
Newsletter sponsorships, featured listings, and sponsored articles.
View packages →